Organogenesis Holdings Inc. ORGO
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Organogenesis Holdings Inc. (ORGO) is a healthcare company listed in the US with a market value of about $105M. In the twelve months to September 30, 2026 it had revenue of $352M and net income of -$135M, a net margin of -38.4%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 11% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.
About Organogenesis
Organogenesis is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $139M in 2016 to $564M in 2025, growth of about 16.9% a year. It was profitable in 6 of the last 10 years in our data. It spends 8% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $352M | $564M | $482M | $433M | $451M | $467M | $338M | $261M | $193M | $199M | $139M |
| Net income | -$135M | $37M | $861000 | $5M | $16M | $94M | $17M | -$39M | -$65M | -$8M | -$17M |
| Free cash flow | -$64000 | -$24M | $4M | $7M | -$9M | $31M | -$12M | -$40M | -$62M | -$6M | -$6M |
| EPS (diluted) | $-1.19 | $0.30 | $-0.01 | $0.04 | $0.12 | $0.70 | $0.15 | $-0.42 | $-0.94 | $-0.14 | $-0.27 |
| Net margin | -38.4% | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% | 5.1% | -14.8% | -33.5% | -4.2% | -12.2% |
| ROIC | — | 9.8% | -0.2% | 2.5% | 4.4% | 15.2% | 11.4% | -23.2% | -73.0% | -7.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Organogenesis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Organogenesis pay a dividend?
Not currently.
Is Organogenesis a good stock to buy?
We do not give buy or sell advice. Organogenesis scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.